Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + dasatinib versus docetaxel + placebo in castration-resistant prostate cancer
RBR-36w269Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Docetaxel + prednisone + dasatinib with Docetaxel + prednisone + placebo (2 arms). Started Jan 2010; status: completed.
02
Drugs
dasatinibdocetaxelprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on RBR-36w269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-36w269.